First-in-human study of the epichaperome inhibitor PU-H71: clinical results and metabolic profile
Conclusions PU-H71 was well tolerated at the doses administered during this study (10 to 470 mg/m2/day), with no dose limiting toxicities.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Cancer | Cancer & Oncology | Drugs & Pharmacology | Genetics | Investigational New Drugs | Study | Toxicology